Filing Flows › Comparisons › GOVX vs NWBO
GeoVax Labs vs Northwest Biotherapeutics: GOVX and NWBO compared
GeoVax Labs is the larger company: $852K of revenue in its latest quarter (Q2 2025) against $807K for Northwest Biotherapeutics (Q2 2026). Northwest Biotherapeutics is growing faster (+516% against +184% a year earlier).
Where the money goes: GOVX and NWBO
GeoVax Labs (GOVX) · Q2 2025
GeoVax Labs, Q2 2025: revenue $852K (+184% year over year), operating margin -635.8%, net loss $5.4M, operating cash flow −$4.3M. The chart follows the revenue to costs, profit and cash.
Northwest Biotherapeutics (NWBO) · Q2 2026
Northwest Biotherapeutics, Q2 2026: revenue $807K (+516% year over year), net loss $15.4M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.
| GeoVax Labs (GOVX) | Northwest Biotherapeutics (NWBO) | |
|---|---|---|
| Latest quarter | Q2 2025 | Q2 2026 |
| Revenue | $852K | $807K |
| Revenue growth, Y/Y | +184% | +516% |
| Operating margin | -635.8% | n/m |
| Net earnings | −$5.4M | −$15.4M |
| Net margin | -630.0% | — |
| Operating cash flow | −$4.3M | −$7.2M |
Questions
Which is bigger, GeoVax Labs or Northwest Biotherapeutics?
GeoVax Labs is the larger company: $852K of revenue in its latest quarter (Q2 2025) against $807K for Northwest Biotherapeutics (Q2 2026).
Is GeoVax Labs or Northwest Biotherapeutics growing faster?
Northwest Biotherapeutics is growing faster (+516% against +184% a year earlier).
More: GeoVax Labs earnings · how GeoVax Labs makes money · Northwest Biotherapeutics earnings · how Northwest Biotherapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Jul 28, 2025; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.